Continuous Antiretroviral Therapy Decreases Bone Mineral Density

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2009 Jun 18

PMID 19531929

Citations 79

Authors

Birgit Grund

Grace Peng

Cynthia L Gibert

Jennifer F Hoy

Rachel L Isaksson

Judith C Shlay

Esteban Martinez

Peter Reiss

Fehmida Visnegarwala

Andrew D Carr

Affiliations

Soon will be listed here.

Abstract

Objectives: To assess the effects of antiretroviral therapy (ART) on bone mineral density (BMD) DESIGN: Randomized comparison of continuous ART (viral suppression group; VS) with intermittent ART (drug conservation group; DC) SETTING: Outpatient clinics in the United States, Australia, and Spain.

Participants: Participants in the Strategies for Management of Antiretroviral Therapy (SMART) Body Composition substudy.

Main Outcome Measures: Annual hip and spine BMD by dual-energy radiographic absorptiometry (DXA) and spine BMD by quantitative computed tomography (qCT).

Methods: Comparisons were by intention-to-treat analysis, using longitudinal models for change in BMD. Risk factors for BMD loss were evaluated.

Results: The 214 participants (median 44 years, 19% female participants, 73% on ART; median T-scores -0.5 total hip, -0.7 spine DXA, -0.9 spine qCT; 98 randomized to VS and 116 to DC) were followed for a mean 2.4 years. With continuous ART, BMD declined per year by 0.8% (hip), 0.4% (spine DXA), and 2.4% (spine qCT). BMD declined significantly less with intermittent ART. Estimated DC minus VS group differences in mean BMD change through follow-up were 1.4% [hip; 95% confidence interval (CI) 0.6-2.3; P = 0.002], 1.3% (spine DXA; 95% CI 0.1-2.4, P = 0.03), and 3.0% (spine qCT; 95% CI 0.8-5.2, P = 0.007). No consistent drug-specific association with BMD decline was found. In the parent study, 10 of 2753 participants in the VS group and two of 2720 in the DC group reported serious fractures (hazard ratio 4.9; 95% CI 1.1-22.5; P = 0.04).

Conclusion: Continuous ART is associated with decline in BMD and possibly more fractures relative to intermittent, CD4 cell count-guided ART.

Citing Articles

Bone Disease in HIV: Need for Early Diagnosis and Prevention.

Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K Life (Basel). 2024; 14(4).

PMID: 38672792 PMC: 11051575. DOI: 10.3390/life14040522.

Non-traumatic Bilateral Lower Limb Fractures in Human Immunodeficiency Virus Positive Individuals on Long-Term Antiretroviral Therapy: Two Case Reports and Literature Review.

Naik K, Dakhode S, Mhaisane S, Nischay K J Orthop Case Rep. 2023; 13(4):16-20.

PMID: 37193378 PMC: 10182575. DOI: 10.13107/jocr.2023.v13.i04.3598.

"We are Getting Those Old People Things." Polypharmacy Management and Medication Adherence Among Adult HIV Patients with Multiple Comorbidities: A Qualitative Study.

Bevilacqua K, Brinkley C, McGowan J, Wallach F, Schwartz R Patient Prefer Adherence. 2022; 16:2773-2780.

PMID: 36311288 PMC: 9604404. DOI: 10.2147/PPA.S382005.

The effect of anti-retroviral therapy on fracture healing : an in vivo animal model.

Graham S, Jalal M, Lalloo D, Simpson A Bone Joint Res. 2022; 11(8):585-593.

PMID: 35942801 PMC: 9396923. DOI: 10.1302/2046-3758.118.BJR-2021-0523.R2.

People living with HIV have low trabecular bone mineral density, high bone marrow adiposity, and poor trabecular bone microarchitecture at the proximal femur.

Carballido-Gamio J, Posadzy M, Wu P, Kenny K, Saeed I, Link T Osteoporos Int. 2022; 33(8):1739-1753.

PMID: 35478045 PMC: 9509414. DOI: 10.1007/s00198-022-06405-y.

References

Yin M, Dobkin J, Brudney K, Becker C, Zadel J, Manandhar M . Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005; 16(11):1345-52. PMC: 3108020. DOI: 10.1007/s00198-005-1845-0. View

Grampp S, Genant H, Mathur A, Lang P, Jergas M, Takada M . Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res. 1997; 12(5):697-711. DOI: 10.1359/jbmr.1997.12.5.697. View

Triant V, Brown T, Lee H, Grinspoon S . Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008; 93(9):3499-504. PMC: 2567857. DOI: 10.1210/jc.2008-0828. View

Brown T, Qaqish R . Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165-74. DOI: 10.1097/QAD.0b013e32801022eb. View

El-Sadr W, Grund B, Neuhaus J, Babiker A, Cohen C, Darbyshire J . Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008; 149(5):289-99. DOI: 10.7326/0003-4819-149-5-200809020-00003. View

Civitelli R, Armamento-Villareal R, Napoli N . Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20(6):843-51. DOI: 10.1007/s00198-009-0838-9. View

Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R . RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol. 2007; 79(10):1446-54. DOI: 10.1002/jmv.20938. View

Nolan D, Upton R, McKinnon E, John M, James I, Adler B . Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001; 15(10):1275-80. DOI: 10.1097/00002030-200107060-00009. View

Brown T, Ruppe M, Kassner R, Kumar P, Kehoe T, Dobs A . Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004; 89(3):1200-6. DOI: 10.1210/jc.2003-031506. View

10.

Fernandez-Rivera J, Garcia R, Lozano F, Macias J, Garcia-Garcia J, Mira J . Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials. 2003; 4(5):337-46. DOI: 10.1310/4X0H-UVMJ-BHYW-CPFB. View

11.

Looker A, Wahner H, Dunn W, Calvo M, Harris T, Heyse S . Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998; 8(5):468-89. DOI: 10.1007/s001980050093. View

12.

Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N . Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008; 22(3):395-402. DOI: 10.1097/QAD.0b013e3282f423dd. View

13.

Bolland M, Grey A, Horne A, Briggs S, Thomas M, Ellis-Pegler R . Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf). 2007; 67(2):270-5. DOI: 10.1111/j.1365-2265.2007.02875.x. View

14.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

15.

Blake G, Fogelman I . The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007; 83(982):509-17. PMC: 2600106. DOI: 10.1136/pgmj.2007.057505. View

16.

Amiel C, Ostertag A, Slama L, Baudoin C, Nguyen T, Lajeunie E . BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004; 19(3):402-9. DOI: 10.1359/JBMR.0301246. View

17.

Anastos K, Lu D, Shi O, Mulligan K, Tien P, Freeman R . The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther. 2007; 12(7):1049-58. DOI: 10.1177/135965350701200701. View

18.

Dolan S, Kanter J, Grinspoon S . Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006; 91(8):2938-45. PMC: 3207203. DOI: 10.1210/jc.2006-0127. View

19.

Arnsten J, Freeman R, Howard A, Floris-Moore M, Lo Y, Klein R . Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007; 21(5):617-23. PMC: 2426821. DOI: 10.1097/QAD.0b013e3280148c05. View

20.

McComsey G, Kendall M, Tebas P, Swindells S, Hogg E, Alston-Smith B . Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007; 21(18):2473-82. DOI: 10.1097/QAD.0b013e3282ef961d. View